Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation

Biochemical and Biophysical Research Communications

Volumn 456, Issue 2, 2015, Pages 683-688

  Happy, Mireille ^a   Dejoie, Jordan ^a   Zajac, Cynthia K ^a   Cortez, Briseida ^a   Chakraborty, Karabi ^a   Aderemi, Joseph ^a   Sauane, Moira ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Apoptosis; ER stress; p38 MAPK; p53; ROS; Sigma 1 Receptor

Indexed keywords

CASPASE 3; CHAPERONE; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RIMCAZOLE; SHORT HAIRPIN RNA; SIGMA 1 OPIATE RECEPTOR; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR; SMALL NUCLEAR RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; UPREGULATION; WESTERN BLOTTING; ADENOVIRIDAE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE THERAPY; GENETICS; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CARBAZOLES; CASPASE 3; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HUMANS; REACTIVE OXYGEN SPECIES; RECEPTORS, SIGMA; RNA, SMALL NUCLEAR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919948886     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.12.029     Document Type: Article

References (32)

1. J. Pflaum, S. Schlosser, and M. Müller p53 family and cellular stress responses in cancer Front. Oncol. 4 2014 285
2. P.A. Muller, and K.H. Vousden Mutant p53 in cancer: new functions and therapeutic opportunities Cancer Cell 25 3 2014 304 317
3. E. Powell, D. Piwnica-Worms, and H. Piwnica-Worms Contribution of p53 to metastasis Cancer Discov. 4 4 2014 405 414
4. H. Tazawa, S. Kagawa, and T. Fujiwara Advances in adenovirus-mediated p53 cancer gene therapy Expert Opin. Biol. Ther. 13 11 2013 1569 1583
5. G.X. Chen, S. Zhang, X.H. He, S.Y. Liu, C. Ma, and X.P. Zou Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives Onco. Targets Ther. 7 2014 1901 1909
6. I.A. Atencio, M. Grace, R. Bordens, M. Fritz, J.A. Horowitz, B. Hutchins, S. Indelicato, S. Jacobs, K. Kolz, D. Maneval, M.L. Musco, J. Shinoda, A. Venook, S. Wen, and R. Warren Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial Cancer Gene Ther. 13 2 2006 169 181
7. S. Idema, M.L. Lamfers, V.W. van Beusechem, D.P. Noske, S. Heukelom, S. Moeniralm, W.R. Gerritsen, W.P. Vandertop, and C.M. Dirven AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy J. Gene Med. 9 12 2007 1046 1056
8. W. Chen, Y. Wu, W. Liu, G. Wang, X. Wang, Y. Yang, W. Chen, Y. Tai, M. Lu, Q. Qian, Q. Zhang, and G. Chen Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma Cancer Lett. 307 1 2011 93 103
9. J. Hasei, T. Sasaki, H. Tazawa, S. Osaki, Y. Yamakawa, T. Kunisada, A. Yoshida, Y. Hashimoto, T. Onishi, F. Uno, S. Kagawa, Y. Urata, T. Ozaki, and T. Fujiwara Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells Mol. Cancer Ther. 12 3 2013 314.S 325.S
10. Collina, R. Gaggeri, and A. Marra Sigma receptor modulators: a patent review Expert Opin. Ther. Pat. 23 5 2013 597 613
11. T.L. Collier, R.N. Waterhouse, and M. Kassiou Imaging sigma receptors: applications in drug development Curr. Pharm. Des. 13 1 2007 51 72
12. A. van Waarde, A.A. Rybczynska, N.K. Ramakrishnan, K. Ishiwata, P.H. Elsinga, and R.A. Dierckx Potential applications for sigma receptor ligands in cancer diagnosis and therapy Biochim. Biophys. Acta 2014 pii: S0005-2736(14)00304-6
13. S. Narayanan, R. Bhat, and C. Mesangeau Early development of sigma-receptor ligands Future Med. Chem. 3 1 2011 79 94
14. T. Hayashi, and M. Fujimoto Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction Mol. Pharmacol. 77 4 2010 517 528
15. T. Hayashi, and T.P. Su Sigma-1 Receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival Cell 131 3 2007 596 610
16. B.A. Spruce, L.A. Campbell, N. McTavish, M.A. Cooper, M.V. Appleyard, M. O'Neill, J. Howie, J. Samson, S. Watt, K. Murray, D. McLean, N.R. Leslie, S.T. Safrany, M.J. Ferguson, J.A. Peters, A.R. Prescott, G. Box, A. Hayes, B. Nutley, F. Raynaud, C.P. Downes, J.J. Lambert, A.M. Thompson, and S. Eccles Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo Cancer Res. 64 14 2004 4875 4886
17. A. van Waarde, A.A. Rybczynska, and N. Ramakrishnan Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands Curr. Pharm. Des. 16 31 2010 3519 3537
18. W. Do, C. Herrera, J. Mighty, M. Shumskaya, S.M. Redenti, and M. Sauane Sigma 1 Receptor plays a prominent role in IL-24-induced cancer-specific apoptosis Biochem. Biophys. Res. Commun. 439 2 2013 215 220
19. L. Wang, J.A. Eldred, and P. Sidaway Sigma 1 Receptor stimulation protects against oxidative damage through suppression of the ER stress responses in the human lens Mech. Ageing Dev. 133 11-12 2012 665 674
20. T. Omi, H. Tanimukai, D. Kanayama, Y. Sakagami, S. Tagami, M. Okochi, T. Morihara, M. Sato, K. Yanagida, A. Kitasyoji, H. Hara, K. Imaizumi, T. Maurice, N. Chevallier, S. Marchal, M. Takeda, and T. Kudo Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor Cell Death Dis. 5 2014 e1332
21. T. Mori, T. Hayashi, E. Hayashi, and T.P. Su Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival PLoS One 8 10 2013 e76941
22. M. Achison, M.T. Boylan, T.R. Hupp, and B.A. Spruce HIF-1alpha contributes to tumour-selective killing by the sigma receptor antagonist rimcazole Oncogene 26 8 2007 1137 1146
23. P.J. Brent, and G.T. Pang Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture Eur. J. Pharmacol. 278 2 1995 151 160
24. K.T. Tchedre, and T. Yorio Sigma-1 Receptors protect RGC-5 cells from apoptosis by regulating intracellular calcium, Bax levels, and caspase-3 activation Invest. Ophthalmol. Vis. Sci. 49 6 2008 2577 2588
25. 2+ entry and transient receptor potential channels by Sigma-1 receptor ligands Br. J. Pharmacol. 168 6 2013 1445 1455
26. A. Pal, D. Fontanilla, A. Gopalakrishnan, Y.K. Chae, J.L. Markley, and A.E. Ruoho The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements Eur. J. Pharmacol. 682 1-3 2012 12 20
27. T. Hayashi, and T.P. Su Regulating ankyrin dynamics: roles of sigma-1 receptors Proc. Natl. Acad. Sci. USA 98 2 2001 491 496
28. N.J. Darling, and S.J. Cook The role of MAPK signalling pathways in the response to endoplasmic reticulum stress Biochim. Biophys. Acta 1843 10 2014 2150 2163
29. J. Meunier, and T. Hayashi Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB J. Pharmacol. Exp. Ther. 332 2 2010 388 397
30. S. Xiong, T. Mu, G. Wang, and X. Jiang Mitochondria-mediated apoptosis in mammals Protein Cell 5 10 2014 737 749
31. S. Kourrich, T.P. Su, M. Fujimoto, and A. Bonci The sigma-1 receptor: roles in neuronal plasticity and disease Trends Neurosci. 35 12 2012 762 771
32. D. Zamanillo, L. Romero, M. Merlos, and J.M. Vela Sigma 1 receptor: a new therapeutic target for pain Eur. J. Pharmacol. 716 1-3 2013 78 93